Purpose: Studies show that Perceval valve for aortic valve replacement (AVR) is associated with postoperative thrombocytopenia. This study aims to compare post-operative thrombocytopenia from Perceval valve in comparison with other bioprosthetic aortic valves based on a systematic review. Methodology: A systematic literature review was conducted in October 2023 based on studies sourced in PubMed/Medline, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and ClinicalTrials.gov. Outcomes assessed included lowest post-operative platelet count, day of lowest post-operative platelet count, platelet transfusion and return to theatre for bleeding re-exploration; in different bioprosthetic valves inclduing Perceval S, Labcor TLPB-A, Hancock II, CE Perimount, Mitroflow, CE Perimount Magna, 3f Enable, Freedom SOLO, Pericarbon Freedom, and Edwards Intuity. Results: All studies comparing Perceval with other bioprosthetic valves revealed that patients receiving Perceval experienced a more significant decrease in platelet counts. This systematic review showed that the utilization of the Perceval valve consistently correlates with a decrease in platelet count from the first to the sixth day after surgery which typically occurs on the second and third post-operative days that leads to a decrease in platelet counts by 30% to 60%. Advanced age, preoperative low platelet count and a sternotomy approach account as significant risk factors for postoperative thrombocytopenia. However, it is important to note that these findings did not result in an increased occurrence of platelet transfusion or return to theatre for post-opertive bleeding. Conclusion: Based on this systematic review, Thrombocytopenia post bioprosthetic aortic valve implantation is common. The decrease in platelet count with Perceval is the highest compare to other bioprtosthetic valves, however, this does not significantly translate into higher morbity.